On Tuesday, 9 September 2025, Amanta Healthcare, a company producing sterile liquid formulations, commenced trading on the stock exchanges after concluding its initial public offering (IPO). Amanta Healthcare shares opened at ₹135 on the NSE, indicating a premium of ₹9, or approximately 7.14%, over the issue price of ₹126. On the BSE, the company’s shares made their debut at ₹134.90, representing an increase of ₹8.90 or roughly 7% over the IPO price.
Strong Investor Response to IPO
The public offering included a fresh issue of 10 million equity shares, aggregating up to ₹126 crore, with the price band set between ₹120 and ₹126 per share and a lot size of 119 shares. Demand for the Amanta IPO was strongest among non-institutional investors (NIIs), who subscribed 209.42 times their allocated shares, followed by retail investors at 54.98 times and qualified institutional buyers (QIBs) at 35.86 times. The allotment process concluded on 4 September 2025, with the final issue price fixed at ₹126 per share, the top of the price band.
For this public issue, MUFG Intime India served as the registrar, while Beeline Capital Advisors acted as the sole book-running lead manager.
Planned Use of IPO Proceeds
According to the company’s Red Herring Prospectus (RHP), the funds raised through the IPO will be primarily utilised for civil construction and the purchase of equipment, plant, and machinery. These investments will facilitate the establishment of a new SteriPort manufacturing line and the expansion of Small Volume Parenterals (SVP) operations at Amanta Healthcare’s facility in Hariyala, Kheda, Gujarat. The remaining funds are earmarked for general corporate purposes, supporting the company’s ongoing growth initiatives.
About Amanta Healthcare
Founded in 1994 and based near Ahmedabad, Gujarat, Amanta Healthcare focuses on the production of sterile liquid parenteral products. Its product portfolio comprises intravenous (IV) fluids, diluents, ophthalmic solutions, respiratory care formulations, irrigation solutions, first-aid supplies, and eye lubricants. The company operates across three core business segments: domestic branded generics, international branded generics, and product partnering with leading pharmaceutical players.
Outlook
The moderate premium at listing reflects steady market confidence in Amanta Healthcare’s business model and long-term growth prospects. With funds from the IPO dedicated to capacity expansion and technology enhancement, the company is well-positioned to strengthen its presence in the sterile liquid product segment both domestically and internationally.
Also Read:
- Shringar House of Mangalsutra IPO: Key Details Investors Shouldn’t Miss
- Jay Ambe Supermarkets IPO Opens: Key Details Investors Shouldn’t Miss
- Galaxy Medicare Ltd. IPO Opens: What Investors Should Know
- Dev Accelerator IPO Opens: What Investors Need to Know
- Urban Company IPO Opens: Key Details Investors Shouldn’t Miss
Conclusion
Amanta Healthcare’s IPO debut marks a significant step in the company’s growth journey. The successful listing, supported by strong investor interest and a clear strategic use of proceeds, provides a solid foundation for future expansion in the pharmaceutical and healthcare industry.
If you are exploring more investment opportunities, check out our dedicated page on upcoming IPO listings to stay updated on the latest market offerings.
